efficacy of glp 1 receptor agonists Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review GLP-1 agonist and safety Trajectory of weight regain after
Description
In analyses stratified by pre-existing diabetes, we found that the increased risk of preterm birth was only present when GLP-1 RAs were used for diabetes treatment: liraglutide (n = 101, aOR 1.70, 95% CI 1.172.48) and semaglutide (n = 110, aOR 1.84, 95% CI 1.242.71) (Fig
Enrolled patients were randomized to once-daily oral Wegovy 25 mg or placebo, as an adjunct to lifestyle intervention for 64 weeks
or are allergic to any of the ingredients in CONTRAVE
Many people start at a low dose and titrate upward to a maintenance level, which can affect side effect patterns
